

### VALUATION SUMMARY

Stocks Undervalued	81.77%	Stocks Overvalued	18.23%
Stocks Undervalued by 20%	50.79%	Stocks Overvalued by 20%	7.15%

ValuEngine currently finds the markets very attractive with over 80% of the approximately 4,000 stocks covered undervalued according to the research.

### INDEX OVERVIEW

Index	Date	Last Close	MTD	QTD	YTD
S&P 500	3/5/2020	3,023.94	2.36%	-6.25%	-6.40%
Dow 30	3/5/2020	26,121.28	2.80%	-7.56%	-8.47%
Nasdaq	3/5/2020	8,738.59	2.00%	-4.51%	-2.61%
Russell 2000	3/5/2020	1,668.47	2.71%	2.10%	23.72%

### PERFORMANCE HISTORY



### SECTOR AVERAGE COMPARISON

Sector Name	Valuation	Momentum	P/E Ratio	Sharpe Ratio
Oils-Energy	47.49% undervalued	-30.77%	16.66	-0.4927
Transportation	32.06% undervalued	-14.02%	14.86	-0.2584
Consumer Discretionary	27.98% undervalued	-15.67%	20.83	-0.1276
Retail-Wholesale	25.06% undervalued	-12.80%	20.48	-0.2061
Multi-Sector Conglomerates	23.96% undervalued	-14.00%	13.12	-0.1275
Basic Materials	22.08% undervalued	-2.86%	22.89	-0.1453
Auto-Tires-Trucks	21.96% undervalued	-15.34%	12.63	-0.2087
Consumer Staples	18.35% undervalued	-4.08%	23.31	-0.0330
Industrial Products	18.12% undervalued	-5.05%	17.30	-0.0014
Finance	17.47% undervalued	-1.80%	14.92	0.0683
Business Services	14.49% undervalued	-1.63%	24.24	-0.0190
Construction	12.79% undervalued	4.73%	20.10	0.0232
Aerospace	11.16% undervalued	1.95%	23.73	0.1557
Computer and Technology	7.66% undervalued	2.12%	30.90	0.0318
Medical	6.74% undervalued	1.90%	29.53	-0.1977
Utilities	3.57% undervalued	8.57%	23.15	0.1635

## TOP INDUSTRIES

Industry Name	Valuation	Momentum	P/E Ratio	Sharpe Ratio	Market Cap (bil)
Medical Services	20.37%	0.63%	23.04	0.0180	2.4254
Securities Exchanges	3.34%	21.49%	30.10	0.6629	28.4260
Nanotechnology	-5.58%	9.78%	27.05	0.2549	1.6295
Solar	-2.92%	24.83%	32.11	-0.1946	1.3617
Medical Information Systems	15.15%	6.88%	34.07	-0.0909	1.8002
Business Information Services	1.25%	42.94%	30.00	0.3943	14.0296
Paints & Allied Products	-5.23%	23.34%	23.74	0.3767	30.0126
Mining-Gold	-16.51%	19.49%	32.22	-0.0459	2.7283
Medical-Biomed/Genetics	0.91%	11.45%	30.04	-0.2165	2.2905
Insurance-Brokers	2.77%	23.78%	24.78	0.3279	13.0544

## STOCK OF THE WEEK - SRPT


Comapny Name: Sarepta Therap

Sector: Medical

Industry: Medical-Biomed/Genetics

## ValuEngine Recommendation

ValuEngine recommendation covers more than 5000 companies. The recommendations are based on the proprietary ValuEngine one-year forecast return model output for each individual equity. ValuEngine's Five-Engine rating stocks have an averaged annual return of 12.07% since 2002.



## Data Summary

Trade Date: Mar 5, 2020	Last Close: \$120.06	Avg Volume: 1106460
1-Yr Forecast: 15.60%	Valuation: 145.32%	1-Yr Momentum: -19.31%
PEG Ratio: 0.36	Market Cap (bil): \$8.95	EPS Growth: 32.41%
Beta: 2.34	5-Yr Avg Return: 42.17%	Volatility: 98.85%
Sharpe Ratio: 0.43	P/S Ratio: 24.51	M/B Ratio: 9.10
Alpha: -0.37	52-Wk High: \$158.80	52-Wk Low: \$72.05

## Forecast Analysis


The predictive variables used in Valuengine's forecast model include both proprietary and well-established variables derived from credible financial studies and publications. We use a distinct forecasting model for each time horizon and apply the most advanced statistical/econometric techniques to ensure that our stock return forecasts are as reliable as possible.

[Click for more information on ValuEngine's models.](#)

	Target Price	Exp. Return
1-Month	\$121.61	1.29%
3-Month	\$126.33	5.22%
6-Month	\$132.03	9.97%
1-Year	\$138.79	15.60%
2-Year	\$127.85	6.49%
3-Year	\$115.08	-4.15%

# STOCK OF THE WEEK - SRPT

## Price And Recommendation History



## ValuEngine Evaluation & Rankings

	Value	Ranking
1-Yr Forecast	15.60%	100
Valuation	145.32%	1
1-Yr Momentum	-19.31%	31
P/E Ratio		20
Market Cap(bil)	8.9493	86
EPS Growth	32.41%	68
5-Yr Avg Return	42.17%	99
Volatility	98.85%	13
Sharpe Ratio	0.4266	86
P/S Ratio	24.51	7
M/B Ratio	9.10	16
Surprise	-74.51%	9

Just as important as the percentages shown for our predictive variables for each stock is the way they are ranked against @7000 stocks in our database. This is sometimes confusing to newcomers to ValuEngine. Each of these quantitative measurements is ranked on a scale of 1 to 100. Generally the higher the ranking, the more positive the influence each measurement has on the overall attractiveness of the stock. In other words a high rank is always better. For example:

- \* Forecast rank 100: 0% of stocks have higher forecast returns.
- \* Valuation rank 1: 99% of stocks are more undervalued.
- \* Momentum rank 31: 69% of stocks have higher momentum.
- \* P/E rank 20: 80% of stocks have lower P/E ratios.
- \* Size rank 86: 14% of stocks have higher market capitalization.
- \* Volatility rank 13: 87% of stocks have less volatility.

## Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.

**VALUENGINE SERVICE DESCRIPTIONS****Investing Should Not Be Emotional**  
**Investing Should Be Based Upon Information & Knowledge**  
**Improve your investment returns with ValuEngine**

ValuEngine provides research on over 5,000 stocks with stock valuations, Buy/Hold/Sell recommendations, and forecasted target prices, so that you the individual investor can make informed decisions, not emotional ones!  
**VE employs a complex Quantitative model that evaluates all available data, all the time.**

**ValuEngine Stock Analysis Service**

- Research on over 4,000 US and 1,000 Canadian stocks
- Updated DAILY (when stock markets open)
- Fair market valuations, forecasted target prices, Buy/Hold/Sell Recommendations
- Industry and Sector Group analysis
- Screener to find top forecasted, or most undervalued stocks (and much more)
- Portfolio functions to maximize performance
- Portfolio wizard to build list of stocks to fit specific investment goals
- Daily Market Bulletin and Weekly newsletters
- Individual stock financials

For more information about ValuEngines research [CLICK HERE](#)

**Two-week Free Trial available!** [CLICK HERE](#)

**ValuEngine Professional Subscription**

- Everything in above Stock Analysis Service, PLUS
- Data file download of ValuEngine research outputs: Valuations, Forecasts, Ratings
- Import portfolio functions
- View unlimited ValuEngine stock reports on over 5,000 companies
- Unlimited access to 16 Sector and over 140 Industry reports
- Track portfolios of unlimited size
- ValuEngine View Portfolio Strategy: Flagship portfolio of 16 stocks
- ValuEngine REIT Strategy: Portfolio of 15 Real estate investment trust stocks
- ValuEngine Diversified Strategy: Portfolio of ETF's for a general market strategy

**Two-week Free Trial available!** [CLICK HERE](#)

**ValuEngine Daily and Weekly Financial Newsletters**

- Published most trading days
- Analysis of various ValuEngine stock picks, newsletters, economic commentary, and market insights
- Additional critical data on market and sector valuations
- Frequently includes links to free ValuEngine stock reports, newsletter samples
- Notification of ValuEngine investor events in your area
- Demonstrates the use of the tools and features at [www.valuengine.com](http://www.valuengine.com)
- Provides analysis for key indices, sectors, and industries
- Analysis of individual stocks that are key in current news cycles
- Provides the latest results for a variety of VE portfolios and newsletters

**For FREE access to ValuEngine blogs and articles!** [CLICK HERE](#)

**Data Feeds/Consultancy**

- Real time data feeds of ValuEngine model outputs
- Quantitative consulting such as model creation, testing, backtesting
- Other customized services

**Please call (321) 325-0519 or contact [support@valuengine.com](mailto:support@valuengine.com)**

## VALUENGINE'S METHODOLOGY

ValuEngine's research combines the most advanced academic concepts with real world Wall Street practice. The result is state-of-the-art fair market valuation and price forecasting technologies.


ValuEngine's stock valuation employs a sophisticated, three-factor approach. Fundamental variables, such as a company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's future 12-month EPS, and the 30-year Treasury yield, are all used to create a more accurate reflection of a company's fair value. Together with eleven additional variables, ValuEngine paints a detailed picture of a company's fair value, represented by the model price.

ValuEngine's stock forecasts capture several important tendencies that stock prices consistently exhibit over six time horizons to ensure forecasts are established relative to a stock's proper peer groups. Advanced statistical/econometric techniques are used to run thousands of simulations estimating the probability of a double in stock price, as well as the probability of meeting and exceeding any given portfolio or stock investment target.

VE Engine Rating is an assessment of a stock's overall attractiveness. It is based on the one year forecast target price, which is the final evolution of VE's equity modeling. On average, only 2 percent of ValuEngine's 5,500 stocks under coverage achieve a 5 rating. 5 and 4 rated stocks are expected to outperform the overall markets, 3 rated to roughly match market performance, and 2 and 1 rated are expected to underperform.

For additional information about ValuEngine's financial research and financial modeling, please click [www.valuengine.com](http://www.valuengine.com)

VE Rating and Average Annual Return  
(Jan 2002 - Feb 2020)



## DISCLOSURES

ValuEngine offers equity recommendations and related return estimates to investors and their advisors. It uses a three-class Buy-Hold-Sell rating system. This is a consolidated version of the firm's five class rating system: most favorable and favorable ratings are buys; neutral ratings are holds and the categories unfavorable and most unfavorable are sells.

**STOCK RATINGS:** The terms below are used to rate a stock's 12-month performance:

1. Buy: Expected to outperform the SP500 producing above average returns.
2. Hold: Expected to perform in line with the SP500 with average returns.
3. Sell: Expected to underperform the SP500 producing below-average returns.

ValuEngine does not offer brokerage or investment banking services. ValuEngine adheres to professional standards and abides by formal codes of ethics that put the interests of clients ahead of their own. The following are specific disclosures made by ValuEngine with regards to this research report:

1. ValuEngine, Inc. does not make a market in this security.
2. ValuEngine, Inc. has not received compensation from the companies discussed above in the last 12 months.
3. ValuEngine has not managed or co-managed a public offering for any companies in the above report in the last 12 months.
4. None of ValuEngine's management, the analysts involved, nor a member of the research analyst's household serves as an officer, director or advisory board member of the companies discussed in this report.
5. The research analyst over this company or members of his/her household do not have a financial interest in these companies discussed in this report.
6. ValuEngine, Inc. or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject companies.
7. Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: a). all of the views expressed accurately reflect his or her personal views about those securities or issuers; and b). no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

## DISCLAIMERS

This report is intended for informational purposes only and does not constitute a recommendation, or an offer, to buy or sell any securities or related financial instruments. The report has no regard to the specific investment objectives, financial situation, or particular needs of any specific recipient. The information contained herein accurately reflects the opinion of ValuEngine at the time the report was released. The opinions of ValuEngine are subject to change at any time without notice and without obligation of notification. ValuEngine does not provide investment banking or consulting services to the companies mentioned in this report. ValuEngine does not receive any compensation from companies mentioned in this report. The author, officers, or affiliates of ValuEngine do not hold positions in the securities of the companies mentioned in this report. No warranty is made as to the accuracy of the information contained herein. This information is intended for the sole use of clients of ValuEngine, Inc. Any other use, distribution, or reproduction is strictly prohibited. Quotes provided by Zacks.